干扰素治疗对慢性乙肝患者外周血趋化因子CCL20、CXCL9、CXCL11的影响
|
摘要
目的探讨应用干扰素治疗慢性乙型肝炎时患者外周血趋化因子CCL20、CXCL9、CXCL11表达水平的变化。方法选取2015年3月—2016年3月在我院就诊的慢性乙肝患者40例作为观察组,使用干扰素进行治疗。同时选择同期于我院进行健康体检的40例健康人作为对照组。在治疗的第4周、第12周、第24周和第48周,采集患者外周血,采用酶联免疫吸附法(enzyme linked immunosorbent assay,ELISA)检测患者血液中趋化因子的表达水平,观察两组之间的差异,同时比较观察组患者在治疗前后,外周血趋化因子的表达水平。结果入院时观察组慢性乙肝患者血清CCL20、CXCL9、CXCL11表达水平[(142.43±36.38)pg/ml、(2 364.08±89.01)pg/ml、(221.2±41.79)pg/ml]均高于健康对照组[(43.57±6.83)pg/ml、(673.44±36.41)pg/ml、(57.89±5.43)pg/ml)],差异具有统计学意义(P<0.05);经干扰素治疗后,观察组患者第12周、第24周、第48周的外周血趋化因子CCL20(t值分别为3.47、3.83、4.29;P分别为0.009、0.006、0.002)、CXCL9(t值分别为2.27、3.29、4.07;P分别为0.027、0.013、0.003)、CXCL11(t值分别为2.05、2.87、3.94;P分别为0.031、0.014、0.004)水平均较治疗前有明显的改善,呈现下降趋势,差异具有统计学意义(P<0.05)。结论干扰素治疗慢性乙肝可降低患者外周血液中CCL20、CXCL9、CXCL11的表达水平,降低慢性乙肝患者血清HBV病毒水平和炎症反应。
Objective To investigate the effect of interferon therapy on the expression of chemokines CCL20, CXCL9 and CXCL11 in peripheral blood of patients with chronic hepatitis B. Methods 40 patients with chronic hepatitis B who were treated with interferon in our hospital from March 2015 to March 2016 were selected as the observation group, and 40 healthy people who did physical examination in the same period in our hospital were selected as the control group. At 4th week, 12 th week, 24 th week and 48 th of the treatment, the peripheral blood of patients was collected and measured by enzyme linked immunosorbent assay(ELISA) to detect the expression level of chemokines in the blood. Results When hospitalized, the levels of serum CCL20, CXCL9 and CXCL11 in the patients with chronic hepatitis B were(142.43 ± 36.38) pg/ml,(2 364.08 ± 89.01) pg/ml,(221.2 ± 41.79) pg/ml, which were significantly higher than those in the control group[(43.57±6.83)pg/ml,(673.44±36.41)pg/ml,(57.89±5.43)pg/ml)],the differences were statistically significant(P< 0.05). After the treatment with interferon, the expression of serum CCL20(t values were 3.47,3.83,4.29; P were 0.009, 0.006, 0.002), CXCL9(t values were 2.27,3.29,4.07; P were 0.027,0.013,0.003) and CXCL11(t values were 2.05,2.87,3.94; P were 0.031,0.014,0.004) were significantly improved compared with those before treatment, and the differences were statistically significant(P<0.05). Conclusion Interferon treatment of chronic hepatitis B can reduce the expression of CCL20, CXCL9 and CXCL11 in peripheral blood of patients, and decrease the levels of serum HBV and serum in patients with chronic hepatitis B.
Objective To investigate the effect of interferon therapy on the expression of chemokines CCL20, CXCL9 and CXCL11 in peripheral blood of patients with chronic hepatitis B. Methods 40 patients with chronic hepatitis B who were treated with interferon in our hospital from March 2015 to March 2016 were selected as the observation group, and 40 healthy people who did physical examination in the same period in our hospital were selected as the control group. At 4th week, 12 th week, 24 th week and 48 th of the treatment, the peripheral blood of patients was collected and measured by enzyme linked immunosorbent assay(ELISA) to detect the expression level of chemokines in the blood. Results When hospitalized, the levels of serum CCL20, CXCL9 and CXCL11 in the patients with chronic hepatitis B were(142.43 ± 36.38) pg/ml,(2 364.08 ± 89.01) pg/ml,(221.2 ± 41.79) pg/ml, which were significantly higher than those in the control group[(43.57±6.83)pg/ml,(673.44±36.41)pg/ml,(57.89±5.43)pg/ml)],the differences were statistically significant(P< 0.05). After the treatment with interferon, the expression of serum CCL20(t values were 3.47,3.83,4.29; P were 0.009, 0.006, 0.002), CXCL9(t values were 2.27,3.29,4.07; P were 0.027,0.013,0.003) and CXCL11(t values were 2.05,2.87,3.94; P were 0.031,0.014,0.004) were significantly improved compared with those before treatment, and the differences were statistically significant(P<0.05). Conclusion Interferon treatment of chronic hepatitis B can reduce the expression of CCL20, CXCL9 and CXCL11 in peripheral blood of patients, and decrease the levels of serum HBV and serum in patients with chronic hepatitis B.
引文
[1]尚鹏程,许娇,裴晓方.慢乙肝和慢重肝患者趋化因子的表达差异及干扰素治疗后的变化[J].现代预防医学,2017,44(5):882-885.
[2]田小利,秦波.趋化因子与干扰素治疗慢性乙型病毒学应答的相关性[J].第三军医大学学报,2012,34(16):1668-1671.
[3]Xiaoqin Lan,Fang Xiao,Qiang Ding,et al.The effect of CXCL9 on the invasionability of epatocellular carcinoma through up-regulation of PREX2[J].Journal of Molecular Histology,2014,45(6):689-696.
[4]中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中华实验和临床感染病杂志:电子版,2015,19(3):1-18.
[5]Huang L,Li J,Yan J,et al.Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy:a randomized controlled trial[J].Journal of viral hepatitis,2013,20(5):336-342.
[6]Wu XY,Li X,Chen ZH,et al.An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy:a pilot study[J].Tumor Biology,2013,34(2):909-918.
[7]Lian JQ,Yang XF,Zhao RR,et al.Expression profiles of circulating cytokines,chemokines and immune cells in patients with hepatitis Bvirus infection[J].Hepatitis Monthly,2014,14(6):e18892.
[8]Xin JJ,Ding WC,Hao SR,et al.Serum macrophage inflammatory protein 3αlevels predict the severity of HBV-related acute-onchronic liver failure[J].Gut,2016,65(2):355-357.
[2]田小利,秦波.趋化因子与干扰素治疗慢性乙型病毒学应答的相关性[J].第三军医大学学报,2012,34(16):1668-1671.
[3]Xiaoqin Lan,Fang Xiao,Qiang Ding,et al.The effect of CXCL9 on the invasionability of epatocellular carcinoma through up-regulation of PREX2[J].Journal of Molecular Histology,2014,45(6):689-696.
[4]中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中华实验和临床感染病杂志:电子版,2015,19(3):1-18.
[5]Huang L,Li J,Yan J,et al.Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy:a randomized controlled trial[J].Journal of viral hepatitis,2013,20(5):336-342.
[6]Wu XY,Li X,Chen ZH,et al.An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy:a pilot study[J].Tumor Biology,2013,34(2):909-918.
[7]Lian JQ,Yang XF,Zhao RR,et al.Expression profiles of circulating cytokines,chemokines and immune cells in patients with hepatitis Bvirus infection[J].Hepatitis Monthly,2014,14(6):e18892.
[8]Xin JJ,Ding WC,Hao SR,et al.Serum macrophage inflammatory protein 3αlevels predict the severity of HBV-related acute-onchronic liver failure[J].Gut,2016,65(2):355-357.